Competition Coming for Myriad's BRCA Test, Whether or Not Gene Patents Hold Up | GenomeWeb

NEW YORK (GenomeWeb News) – In the next few years, or perhaps even sooner, Myriad may be at risk of losing its grip over the lucrative BRCA testing franchise in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.